Staging preview: health content pending qualified review
D2C Peptides

Dosage information

KLOW Peptide Blend dosage

No human dose of KLOW has been established, and no published study has given the blend to animals or people.12 The amounts on this page come from studies of its single parts: animal studies, small BPC-157 studies in people, and trials of thymosin beta-4 and a GHK-copper gel. They record what researchers used, not guidance for anyone.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

No dose has been set for people

No human dose of KLOW has been worked out: no published study has given the blend to animals or people,1 so there is no tested amount, schedule or length of use. The gap extends to its parts: a 2026 review of injectable peptides used in sports medicine states that their indications, dosing, frequency and duration of treatment remain unknown.2 USADA adds that, because BPC-157 has had little study in people, it is unknown whether any dose is safe.3

FDA's 2026 reviews show how thin the human record is. FDA found no study that gave BPC-157 to people under the skin, by mouth, by nasal spray or through the skin,4 no article in which TB-500 was given to people,5 and no data, such as clinical studies, on KPV use in humans.6

Amounts used in published studies

These are the amounts researchers used for KLOW's single parts, with species, route and length. They describe the studies, not a dose for anyone, and this page does not convert animal amounts into human ones.

Peptide Study Subjects Route Amount and schedule
BPC-157 Achilles tendon (2003) Rats with a cut tendon Into the abdominal cavity (intraperitoneal) 10 µg/kg, 10 ng/kg or 10 pg/kg once daily from 30 minutes after surgery, assessed on days 1, 4, 7, 10 and 147
BPC-157 and TB-500 Achilles tendon repair (2026) 32 male rats Intraperitoneal BPC-157 10 µg/kg/day and TB-500 60 µg/kg/day, alone or together, for 4 weeks89
BPC-157 Enema studies (meeting abstracts) 24 healthy volunteers Rectal enema Up to 2 mg/kg once daily for 8 days10
BPC-157 Ulcerative colitis trial (2005 abstract) 53 people, BPC-157 or placebo Rectal enema 80 mg once daily for 2 weeks11
BPC-157 Knee pain chart review (2021) 17 people, as counted by FDA Into the knee joint 2 to 4 mg, 1 or 2 doses10
BPC-157 Interstitial cystitis pilot (2024) 12 women aged 39 to 76 Injections around the bladder 10 mg in total, in one procedure12
BPC-157 IV safety pilot (2025) 2 healthy adults IV infusion 10 mg on day 1, then 20 mg on day 213
TB-500 Blood-level study (2012) Thoroughbred geldings Under the skin One 10 mg dose5
Thymosin beta-4, not TB-500 Phase 1 trial (2010) 40 healthy volunteers in 4 groups of 10 IV 42, 140, 420 or 1,260 mg once, then daily for 14 days14
Thymosin beta-4, not TB-500 Phase 2 dry eye trial (2015) 9 people with severe dry eye Eye drops 0.1% drops 6 times daily for 28 days15
KPV Colitis study (2008) Mice, 10 per group In drinking water 100 µM for 8 days16
GHK-Cu Muscle-loss study (2023) Mice exposed to cigarette smoke Intraperitoneal 0.2 or 2 mg/kg once a week for 7 weeks17
GHK-Cu Diabetic ulcer trial (1994) People with diabetic neuropathic ulcers Gel on the skin A metered amount daily; gel strength not given in the abstract18

Why these amounts do not carry over to a KLOW vial

  • Unknown split. The vial states a 70 mg total, not the amount of each peptide, so no part of it can be matched to a BPC-157, TB-500, KPV or GHK-Cu amount in the table.
  • Different molecules. The two thymosin beta-4 trials tested the full-length peptide,1415 and FDA states that thymosin beta-4 and TB-500 are not the same substance.5
  • Different routes. The studies used enemas, eye drops, a skin gel, drinking water, IV infusion, and injections under the skin or into the abdomen, knee or bladder. Route changes what reaches the blood: in two human enema studies, BPC-157 was not detected in blood plasma.19
  • One or two peptides at a time. The one controlled study in the table that combined two of KLOW's parts, BPC-157 with TB-500 in rats, found no added benefit from combining them.8

How fast the parts clear

Data on how quickly KLOW's parts leave the body come from single doses in animals. After one IV dose, BPC-157's half-life was 5.3 minutes in dogs and 15.2 minutes in rats.19 In horses given 10 mg of TB-500 under the skin, blood levels peaked 1 to 2 hours after dosing and could no longer be measured 6 to 10 hours after dosing.5 FDA found no human pharmacokinetic studies of TB-5005 and no human data for KPV.6 Single-dose animal figures like these do not set a schedule for people.

Lab amounts are not doses

Dissolving the powder in a measured volume of diluent gives a total peptide concentration in mg per mL. That number describes a lab solution, not a dose, and for KLOW it cannot be split into the concentration of each peptide. The reconstitution calculator and the peptide calculator do this arithmetic, and general background is in Peptide dosage basics.

Start with the full profile, What is KLOW Peptide Blend?. What the studies above found is summarized in KLOW Peptide Blend benefits and uses, and reported harms in KLOW Peptide Blend side effects. Single-peptide pages: TB-500 dosage, KPV dosage and What is BPC-157?. The related three-peptide blend is covered in Glow Peptide Stack dosage.

More on KLOW Peptide Blend

  • KLOW Peptide Blend benefits and uses

    What published sources report about KLOW Peptide Blend and its uses, with the evidence level of each finding. No promises.

  • KLOW Peptide Blend side effects

    Side effects of KLOW Peptide Blend as reported in studies and FDA reports on its four parts, with links to the full profile. No study has tested the blend.

KLOW Peptide Blend in the store

KLOW Peptide Blend for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

How long do you stay on KLOW peptide?

No length of use has been tested. No study has given KLOW to anyone,1 and a 2026 review states that the duration of treatment for injectable peptides like its parts remains unknown.2 The studies in the table ran from a single dose up to 7 weekly doses in mice, 4 weeks of daily doses in rats and 28 days of daily eye drops in people.517815 FDA found no repeat-dose toxicity study of BPC-157 longer than 28 days.20

Is there a dosing schedule for KLOW?

No. No schedule has been established for KLOW or for any of its parts in people.12 A 2026 review states that the frequency of treatment for injectable peptides like these remains unknown,2 and FDA found no human pharmacokinetic studies of TB-500.5 The animal data on how fast the parts clear come from single doses, such as a BPC-157 half-life of minutes in rats and dogs,19 and they do not define a schedule for people.

How much is KLOW peptide per month?

Any monthly figure would assume a dose and schedule, and none has been established for KLOW in people.23 The vial also does not disclose how its total divides between BPC-157, TB-500, KPV and GHK-Cu, so it cannot be split into known amounts of any one peptide. The product page, KLOW Peptide Blend for sale, lists the vial for laboratory research under the research use policy.

Can a human dose be worked out from the rat studies?

No dose for people can be read from these studies. The rat amounts were injected into the abdominal cavity, per kilogram of body weight, after one surgical injury, and they covered one or two peptides, not four.78 No human trial has confirmed any of them, and a 2026 review states that dosing for these injectable peptides remains unknown.2 KLOW's split between its four peptides is also not disclosed, so even a known single-peptide amount could not be located in the vial.

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. PubMed search: (BPC-157 OR "BPC 157") AND KPV AND GHK. National Library of Medicine (PubMed E-utilities), 2026.
  2. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (Mayfield CK et al.): GHK-Cu and dosing. American Journal of Sports Medicine, 2026.
  3. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide (health risks). U.S. Anti-Doping Agency (USADA).
  4. FDA presentations, Pharmacy Compounding Advisory Committee, July 23, 2026: BPC-157 routes studied and immunogenicity. U.S. Food and Drug Administration, 2026.
  5. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). U.S. Food and Drug Administration, 2026.
  6. Same source as 4: KPV evaluation and recommendation.
  7. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth (Staresinic M, et al.; PMID 14554208). Journal of Orthopaedic Research (PubMed abstract via NCBI E-utilities), 2003.
  8. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer O et al.). Joint Diseases and Related Surgery, 2026.
  9. Same source as 8: Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (Biçer O et al.): biomechanics.
  10. Same source as 4: BPC-157 doses used in clinical studies.
  11. Same source as 4: BPC-157 ulcerative colitis effectiveness.
  12. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (Lee E et al.): design and safety. Alternative Therapies in Health and Medicine, 2024.
  13. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (Lee E, Burgess K). Alternative Therapies in Health and Medicine, 2025.
  14. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (Ruff D et al.). Annals of the New York Academy of Sciences, 2010.
  15. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Sosne G et al.). Cornea, 2015.
  16. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Dalmasso G et al.), full text [PMC2431115]. Gastroenterology (full text via PubMed Central, NIH/NLM), 2008.
  17. Deng M, et al. Glycyl-l-histidyl-l-lysine-Cu2+ rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway (full text, Figure 4 legend). Journal of Cachexia, Sarcopenia and Muscle, 2023.
  18. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (Mulder GD et al.). Wound Repair and Regeneration, 1994.
  19. Same source as 4: BPC-157 pharmacokinetics.
  20. Same source as 4: BPC-157 nonclinical safety.